Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 13;222(12):2052-2060.
doi: 10.1093/infdis/jiaa306.

Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men-United States, 2016-2018

Elissa Meites  1 , Rachel L Winer  2 , Michael E Newcomb  3 , Pamina M Gorbach  4 , Troy D Querec  5 , Jessica Rudd  6 , Tom Collins  7 , John Lin  2 , Janell Moore  4 , Thomas Remble  3 , Fred Swanson  8 , Justin Franz  3 , Robert K Bolan  9 , Matthew R Golden  10 , Brian Mustanski  3 , Richard A Crosby  7 , Elizabeth R Unger  5 , Lauri E Markowitz  1
Affiliations

Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men-United States, 2016-2018

Elissa Meites et al. J Infect Dis. .

Abstract

Background: In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011.

Methods: The Vaccine Impact in Men study surveyed MSM and transgender women aged 18-26 years in 3 US cities during 2016-2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI).

Results: Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at age ≤18 years was 0.41 (CI, 0.24-0.57) and at age >18 years was 0.82 (CI, 0.67-0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at age ≤18 years or >18 years was 59% and 18%, respectively.

Conclusions: Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination.

Keywords: papillomavirus infections; papillomavirus vaccines; sexual and gender minorities; vaccination.

PubMed Disclaimer

References

    1. Nyitray AG , Carvalho da Silva RJ, Baggio ML, et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis 2011; 203:49–57. - PMC - PubMed
    1. Marra E , Lin C, Clifford GM. Type-specific anal human papillomavirus prevalence among men, according to sexual preference and HIV status: a systematic literature review and meta-analysis. J Infect Dis 2019; 219:590–8. - PubMed
    1. Machalek DA , Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13:487–500. - PubMed
    1. Garland SM , Hernandez-Avila M, Wheeler CM, et al. ; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928–43. - PubMed
    1. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915–27. - PubMed

Publication types

MeSH terms

Substances